Back to Journals » Journal of Pain Research » Volume 11

Buprenorphine and pain treatment in pediatric patients: an update

Authors Vicencio-Rosas E, Pérez-Guillé MG, Flores-Pérez C, Flores-Pérez J, Trujillo-Jiménez F, Chávez-Pacheco JL

Received 12 October 2017

Accepted for publication 29 November 2017

Published 15 March 2018 Volume 2018:11 Pages 549—559


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr E Alfonso Romero-Sandoval

Erendira Vicencio-Rosas,1 María Gabriela Pérez-Guillé,2 Carmen Flores-Pérez,2 Janett Flores-Pérez,2 Francisca Trujillo-Jiménez,2 Juan Luis Chávez-Pacheco2

1Anesthesiology Department, Hospital Regional de Alta Especialidad “Bicentenario de la Independencia”, ISSSTE, Tultitlán de Mariano Escobedo, México; 2Pharmacology Laboratory, Instituto Nacional de Pediatría, Ciudad de México, México

The usual management of moderate to severe pain is based on the use of ­opioids. Buprenorphine (BPN) is an opioid with an analgesic potency 50 times greater than that of morphine. It is widely used in various pain models and has demonstrated efficacy and safety in adult patients; however, there are insufficient clinical trials in pediatric populations.
Purpose: The aim of this study was to perform an updated meta-analysis on the implementation of BPN in the treatment of pain in the pediatric population.
Methods: A bibliographic search was carried out in different biomedical databases to identify scientific papers and clinical trials with evidence of BPN use in children and adolescents.
Results: A total of 89 articles were found, of which 66 were selected. Analysis of these items revealed additional sources, and the final review included a total of 112 publications.
Conclusion: Few studies were found regarding the efficacy and safety of BPN use in children. In recent years, the use of this drug in the pediatric population has become widespread, so it is imperative to perform clinical trials and pharmacological and pharmacovigilance studies, which will allow researchers to develop dosage schemes based on the evidence and minimize the risk of adverse effects.

Keywords: buprenorphine, opioid, analgesia, child, adverse effects, pharmacokinetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]